查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1841936

药物定序人工智慧的全球市场：市场规模、份额和趋势分析（按组件、技术、最终用途和地区）、按细分市场预测（2025-2033 年）

AI In Drug Repurposing Market Size, Share & Trends Analysis Report By Component, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

药物定序人工智慧市场摘要

预计 2024 年全球药物定序人工智慧市场价值将达到 10.2 亿美元，到 2033 年将达到 54.8 亿美元，2025 年至 2033 年的复合年增长率为 20.39%。

对具有成本效益的药物开发的需求不断增长、人工智慧演算法的进步以及罕见和复杂疾病的日益流行是推动市场成长的主要因素。

此外，製药公司、学术机构和人工智慧技术供应商之间的合作日益增多，以及运算能力和云端基础设施的改进也是推动成长的其他因素。

对具有成本效益的药物开发策略日益增长的需求是人工智慧在药物定序发展的主要驱动力。传统药物研发需要超过 10 年的漫长时间，每种药物的成本通常超过 20 亿美元。药物再利用提供了一种策略，透过专注于已已通过核准或正在进行新适应症临床实验的药物来避免早期安全性测试。人工智慧透过快速分析大量生物、化学和临床数据集并识别新的药物-疾病关係来加速这一过程。这缩短了开发时间和成本，为製药公司和医疗保健提供者提供了一种经济可行的新药开发替代方案。将人工智慧与药物再利用相结合可以有效应对关键的行业挑战，提高生产力，同时降低相关风险和投资。

人工智慧系统将多体学数据（包括基因组学、蛋白质组学和代谢体学）与生物医学文献和实际患者记录相结合，以识别以前未被认识的微妙的药物-标靶相互作用。这些方法能够识别多药理学候选药物和协同药物组合，克服了传统基于假设的发现的限制。例如，2025 年 4 月，Plex Research 与 Ginkgo Bioworks 合作，对 GDPx2 资料集进行人工智慧辅助分析，这是一项关于化合物基因表现的大规模转录组学研究。此次合作旨在加速识别新的疾病机制、发现新的治疗应用以及重新利用药物。研究结果将与实验数据相关联并经过严格检验。

此外，罕见疾病的日益普及也进一步推动了市场的成长。例如，根据《采血针2024年3月发布的数据，全球将有约3亿人罹患罕见疾病，约占全球人口的3.5%至5.9%。此外，约80%的罕见疾病是遗传性疾病，其中近70%在儿童时期发病。人工智慧可以促进对罕见疾病患者群体有限资料集的分析，并从现有药物中识别候选治疗方案，从而加速治疗的可及性。

目录

第一章 分析方法与范围

第二章执行摘要

第三章：人工智慧药物定序市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
    • 市场机会分析
    • 市场问题分析
  • 药物定序人工智慧市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
  • 案例研究
  • 技术分析：关键用例和应用领域
    • 机器学习（ML）/深度学习
    • 自然语言处理（NLP）
    • 生成式人工智慧和大规模语言模型（LLM）

第四章：药物定序人工智慧市场：按组成部分的估计和趋势分析

  • 细分仪表板
  • 药物定序人工智慧市场：各成分波动分析
  • 药物定序人工智慧市场：市场规模预测与各组成部分趋势分析（2021-2033）
  • 软体平台
  • 服务

第五章：药物定序人工智慧市场：依技术估算与趋势分析

  • 细分仪表板
  • 药物定序的人工智慧市场：技术变化分析
  • 药物定序人工智慧：市场规模预测与技术趋势分析（2021-2033）
  • 机器学习/深度学习
  • 自然语言处理（NLP）
  • 知识图谱和基于网路的人工智慧
  • 生成式人工智慧和大规模语言模型（LLM）
  • 电脑视觉

第六章：药物定序人工智慧市场：按应用估算与趋势分析

  • 细分仪表板
  • 药物定序人工智慧市场：应用变化分析
  • 药物定序人工智慧市场：按应用分類的市场规模预测与趋势分析（2021-2033）
  • 瘤
  • 神经系统疾病
  • 心臟病
  • 感染疾病
  • 罕见疾病
  • 其他治疗领域

第七章：人工智慧药物定序市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 药物定序市场的人工智慧：按最终用途进行的变化分析
  • 药物定序人工智慧市场：按最终用途分類的市场规模预测和趋势分析（2021-2033 年）
  • 製药和生物技术公司
  • CRO（委外研发机构）
  • 学术和研究机构
  • 其他的

第 8 章：药物定序人工智慧市场：区域估计与趋势分析

  • 各地区市占率（2024 年及 2033 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 公司/竞争对手分类
  • 战略地图
  • 企业市场分析（2024年）
  • 公司简介/上市公司
    • BostonGene Corporation
    • Ginkgo Bioworks
    • IBM
    • TxGNN
    • BioXcel Therapeutics Inc.
    • BullFrog AI Holdings, Inc.
    • Ignota Labs
    • ISOMORPHIC LABS
    • Insilico Medicine
    • Healx
Product Code: GVR-4-68040-755-3

AI In Drug Repurposing Market Summary

The global AI in drug repurposing market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 20.39% from 2025 to 2033. Rising demand for cost-effective drug development, advancements in AI algorithms, and the growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers, and improvements in computing power and cloud infrastructure are some other factors fueling the growth.

The rising demand for cost-effective drug development strategies substantially drives the growth of the AI in drug repurposing industry. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global AI In Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in drug repurposing market report based on component, technology, application, end use, and region:

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software & Platforms
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Machine Learning/Deep Learning
  • Natural Language Processing (NLP)
  • Knowledge Graphs & Network-Based AI
  • Generative AI & Large Language Models (LLMs)
  • Computer Vision
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Rare & Orphan Diseases
  • Other Therapeutic Areas
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Component Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. AI in Drug Repurposing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for cost-effective drug development,
      • 3.2.1.2. Advancements in AI algorithms
      • 3.2.1.3. Increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers,
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Data security and privacy concerns
      • 3.2.2.2. High computational costs and infrastructure requirements
    • 3.2.3. Market opportunity analysis
    • 3.2.4. Market challenges analysis
  • 3.3. AI in Drug Repurposing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape
  • 3.4. Case Studies
  • 3.5. Technology Analysis: Key Use Cases and Application
    • 3.5.1. Machine Learning (ML)/Deep Learning
    • 3.5.2. Natural Language Processing (NLP)
    • 3.5.3. Generative AI & Large Language Models (LLMs)

Chapter 4. AI in Drug Repurposing Market: Component Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global AI in Drug Repurposing Market Component Movement Analysis
  • 4.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
  • 4.4. Software & Platforms
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. AI in Drug Repurposing Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global AI in Drug Repurposing Market Technology Movement Analysis
  • 5.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Machine Learning/Deep Learning
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Natural Language Processing (NLP)
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Knowledge Graphs & Network-Based AI
    • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Generative AI & Large Language Models (LLMs)
    • 5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.8. Computer Vision
    • 5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. AI in Drug Repurposing Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global AI in Drug Repurposing Market Application Movement Analysis
  • 6.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Neurology
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Cardiology
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Infectious Diseases
    • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.8. Rare & Orphan Diseases
    • 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.9. Other Therapeutic Areas
    • 6.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. AI in Drug Repurposing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global AI in Drug Repurposing Market End Use Movement Analysis
  • 7.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Contract Research Organizations (CROs)
    • 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Academic & Research Institutes
    • 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. AI in Drug Repurposing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.6. Norway
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. BostonGene Corporation
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Ginkgo Bioworks
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. IBM
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. TxGNN
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. BioXcel Therapeutics Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. BullFrog AI Holdings, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Ignota Labs
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. ISOMORPHIC LABS
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Insilico Medicine
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Healx
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global AI in drug repurposing market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 4 Global AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 6 Global AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 9 North America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 10 North America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 12 U.S. AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 13 U.S. AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 14 U.S. AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 15 U.S. AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Canada AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 17 Canada AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 18 Canada AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Mexico AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 21 Mexico AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 22 Mexico AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 23 Mexico AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Europe AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 25 Europe AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 26 Europe AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 27 Europe AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Europe AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 29 UK AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 30 UK AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 31 UK AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Germany AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 34 Germany AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 35 Germany AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Germany AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 37 France AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 38 France AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 39 France AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 40 France AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Italy AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 42 Italy AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 43 Italy AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Spain AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 46 Spain AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 47 Spain AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Spain AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Denmark AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 50 Denmark AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 51 Denmark AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Denmark AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Sweden AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 54 Sweden AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 55 Sweden AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Sweden AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Norway AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 58 Norway AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 59 Norway AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Norway AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 66 China AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 67 China AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 68 China AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 China AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Japan AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 71 Japan AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 72 Japan AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Japan AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 74 India AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 75 India AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 76 India AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 India AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Korea AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 79 South Korea AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 80 South Korea AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 South Korea AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Australia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 83 Australia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 84 Australia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Australia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 86 Thailand AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 87 Thailand AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 88 Thailand AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Thailand AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Latin America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Latin America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 92 Latin America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 93 Latin America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 94 Latin America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 95 Brazil AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 96 Brazil AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 97 Brazil AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 98 Brazil AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 99 Argentina AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 100 Argentina AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 101 Argentina AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 102 Argentina AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 MEA AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 104 MEA AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 105 MEA AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 106 MEA AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 107 MEA AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 108 South Africa AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 109 South Africa AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 110 South Africa AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 111 South Africa AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 116 UAE AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 117 UAE AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 118 UAE AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 119 UAE AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 120 Kuwait AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 121 Kuwait AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 122 Kuwait AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 123 Kuwait AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Market formulation & validation
  • Fig. 5 AI in drug repurposing market: Market outlook
  • Fig. 6 AI in drug repurposing market: Segment outlook
  • Fig. 7 AI in drug repurposing market: Competitive landscape outlook
  • Fig. 8 Parent market outlook
  • Fig. 9 AI in drug repurposing market driver impact
  • Fig. 10 AI in drug repurposing market restraint impact
  • Fig. 11 AI in drug repurposing market: Component outlook and key takeaways
  • Fig. 12 AI in drug repurposing market: Component movement analysis
  • Fig. 13 Software & platform market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 14 Services market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 15 AI in drug repurposing market: Technology outlook and key takeaways
  • Fig. 16 AI in drug repurposing market: Technology movement analysis
  • Fig. 17 Machine learning/deep learning market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Natural language processing (NLP) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Knowledge graphs & network-based AI market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Generative AI & large language models (LLMs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Computer vision market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 AI in drug repurposing market: Application outlook and key takeaways
  • Fig. 23 AI in drug repurposing market: Application movement analysis
  • Fig. 24 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Neurology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Cardiology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Rare & orphan diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Other therapeutic areas market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 AI in drug repurposing market: End use outlook and key takeaways
  • Fig. 31 AI in drug repurposing market: End use movement analysis
  • Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Contract research organizations (CROs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Global AI in drug repurposing market: Regional outlook and key takeaways
  • Fig. 37 Global AI in drug repurposing market: Regional movement analysis
  • Fig. 38 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)